Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 15980
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
GI Innovation, Inc. engages in the development of biopharmaceutical products. Its product pipeline includes G-101, G-102, G-301, and G-108. The company was founded by Jang Myoung-ho on July 19, 2017 and is headquartered in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell